Is Vasopressin Legit? Evidence Grade and Plain-English Verdict
Vasopressin is rated Level A. The short verdict: Vasopressin (Vasostrict) is FDA-approved for vasodilatory shock (septic shock, post-cardiotomy vasodilatory shock) with Phase 3 evidence from the VASST trial showing non-inferiority to norepinephrine and steroid-sparing potential in septic shock. As an endogenous hormone with a distinct vasoconstrictive mechanism, it is a standard vasopressor in critical care medicine.
Direct Answer
Vasopressin (Vasostrict) is FDA-approved for vasodilatory shock (septic shock, post-cardiotomy vasodilatory shock) with Phase 3 evidence from the VASST trial showing non-inferiority to norepinephrine and steroid-sparing potential in septic shock. As an endogenous hormone with a distinct vasoconstrictive mechanism, it is a standard vasopressor in critical care medicine.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Best for
- Vasodilatory shock, septic shock vasopressor therapy, V1a/V2 receptor pharmacology research
Why the Claim Is Strong or Weak
Vasopressin (antidiuretic hormone/ADH) is a naturally occurring nonapeptide hormone. Synthetic vasopressin is FDA-approved for vasodilatory shock, diabetes insipidus, and as an adjunct in cardiac arrest.
As of April 2026, 115 new paper(s) published in PubMed including: Hemodynamic rescue after blast injury: intravenous administration outperforms intramuscular vasopressin in a swine model.
Top Evidence Signals
- Vasodilatory Shock Treatment: Level A, includes human evidence - Russell et al. (2008, N Engl J Med, VASST trial, n=778) showed low-dose vasopressin (0.01-0.03 U/min) combined with norepinephrine did not reduce 28-day mortality overall vs. norepinephrine alone, but a pre-specified subgroup with less severe shock (NE 5-14 ug/min) had lower mortality (26.5% vs. 35.7%, p=0.05); Gordon et al. (2016, VANISH trial, n=409) confirmed vasopressin reduced renal failure incidence.
- Diabetes Insipidus Management: Level A, includes human evidence - Effectively controls polyuria and polydipsia in central diabetes insipidus by replacing deficient endogenous vasopressin. Gold standard for acute management.
- Cardiac Arrest Adjunct: Level B, includes human evidence - Used as alternative or adjunct to epinephrine in cardiac arrest algorithms. Some evidence of benefit in asystolic arrest, though overall evidence for improved outcomes is mixed.
Where Claims Usually Overreach
- Water intoxication/hyponatremia risk with excessive doses
- Digital and mesenteric ischemia - monitor extremities
- Cardiac ischemia risk - use with caution in coronary artery disease
- Extravasation can cause tissue necrosis
- Can cause uterine contractions - use caution in pregnancy
Primary Sources
- Vasopressin versus norepinephrine infusion in patients with septic shock (VASST). N Engl J Med, 2008.
- Vasopressin in hemorrhagic shock: a systematic review and meta-analysis. Resuscitation, 2015.
- A randomized clinical trial of vasopressin and epinephrine for in-hospital cardiac arrest. Resuscitation, 2012.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Vasodilatory Shock Treatment (Level A), Diabetes Insipidus Management (Level A), and Cardiac Arrest Adjunct (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Is Vasopressin Legit? Evidence Grade and Plain-English Verdict." Last reviewed 2026-04-04. https://examinepeptides.com/answers/is-vasopressin-legit/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.